<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1029-3019</journal-id>
<journal-title><![CDATA[MEDISAN]]></journal-title>
<abbrev-journal-title><![CDATA[MEDISAN]]></abbrev-journal-title>
<issn>1029-3019</issn>
<publisher>
<publisher-name><![CDATA[Centro Provincial de Información de Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1029-30192021000601297</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Utilidad del HeberFERON® en pacientes con carcinoma basocelular]]></article-title>
<article-title xml:lang="en"><![CDATA[Usefulness of HeberFERON® in patients with basal cell carcinoma]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López Pupo]]></surname>
<given-names><![CDATA[Natacha]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Manganelly Fonseca]]></surname>
<given-names><![CDATA[Yarien]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tablada Robinet]]></surname>
<given-names><![CDATA[María Elena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jacas Portuondo]]></surname>
<given-names><![CDATA[Ana Lucía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Girón Maturell]]></surname>
<given-names><![CDATA[Yaimaris]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Docente Dr. Juan Bruno Zayas Alfonso  ]]></institution>
<addr-line><![CDATA[Santiago de Cuba ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>25</volume>
<numero>6</numero>
<fpage>1297</fpage>
<lpage>1308</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1029-30192021000601297&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1029-30192021000601297&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1029-30192021000601297&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  El carcinoma basocelular es el tumor epitelial maligno más frecuente, pues constituye 60-80 % de todos los cánceres cutáneos.  Objetivo:  Determinar la respuesta al HeberFERON® en pacientes con carcinoma basocelular.  Métodos:  Se realizó un estudio observacional, descriptivo y longitudinal de 90 pacientes con carcinoma basocelular, a quienes se le administró HeberFERON® en el Hospital General Docente Dr. Juan Bruno Zayas Alfonso de Santiago de Cuba, desde enero de 2017 hasta diciembre de 2019. Se analizaron variables demográficas, clínicas y de respuesta al tratamiento.  Resultados:  La edad promedio fue de 63 años; hubo una mayor incidencia del sexo masculino (58 para 64,4 %) y el fototipo cutáneo II (56 para 62,0 %), con lesiones localizadas en la nariz (42 para 46,7 %), así como un predominio del subtipo clínico nodular (41 para 45,6 %). Se logró el control de la enfermedad en 100,0 % de la casuística.  Conclusiones:  El HeberFERON® resultó de gran utilidad en los pacientes con carcinoma basocelular, puesto que en más de la mitad de ellos se obtuvo una respuesta completa, con un mínimo de eventos adversos, todos leves y moderados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: The basal cell carcinoma is the most frequent epithelial neoplasm, because it constitutes 60-80 % of all the cutaneous cancers. Objective: To determine the answer to HeberFERON® in patients with basal cell carcinoma.  Methods: An observational, descriptive and longitudinal study of 90 patients with basal cell carcinoma to whom HeberFERON® was administered was carried out at Dr. Juan Bruno Zayas Alfonso Teaching General Hospital in Santiago de Cuba, from January, 2017 to December, 2019. Some demographic, clinical variables that responded to the treatment were analyzed.  Results: The average age was 63 years; there was a higher incidence of the male sex (58 for 64.4 %) and the cutaneous fototype II (56 for 62.0 %), with lesions located in the nose (42 for 46.7 %), as well as a prevalence of the nodular clinical subtype (41 for 45.6 %). The control of the disease was achieved in 100.0 % of the case material.  Conclusions: The HeberFERON® was very useful in patients with basal cell carcinoma, since in more than a half of them a complete response was obtained, with a minimum of adverse events, all of them light and moderate.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[cáncer de piel]]></kwd>
<kwd lng="es"><![CDATA[carcinoma basocelular]]></kwd>
<kwd lng="es"><![CDATA[inmunoterapia]]></kwd>
<kwd lng="es"><![CDATA[HeberFERON®]]></kwd>
<kwd lng="en"><![CDATA[skin cancer]]></kwd>
<kwd lng="en"><![CDATA[basal cell carcinoma]]></kwd>
<kwd lng="en"><![CDATA[immunotherapy]]></kwd>
<kwd lng="en"><![CDATA[HeberFERON®]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piña Rodríguez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Piña Russinyol]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Piña Rodríguez]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Castro Morillo]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Darias Domínguez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dermatoscopia para establecer márgenes quirúrgicos mínimos en la resección de carcinomas basocelulares]]></article-title>
<source><![CDATA[Rev. méd. electrón]]></source>
<year>2018</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology, pathogenesis, and clinical features of basal cell carcinoma]]></article-title>
<source><![CDATA[UpToDate]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez Fonseca]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[de la Rosa Santana]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[López Wilson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Santiesteban Puerta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera Pérez]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento con HeberFERON(r) en pacientes con carcinoma basocelular del Hospital Clínico Quirúrgico "Dr. Miguel Enríquez", La Habana. 2018]]></article-title>
<source><![CDATA[Gac méd estud]]></source>
<year>2020</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>122-32</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>Cuba. Ministerio de Salud Pública</collab>
<source><![CDATA[Anuario Estadístico de Salud. Dirección de Registros Médicos y Estadísticas de Salud 2017]]></source>
<year>2018</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cabrera Naranjo]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Linares]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Román Simón]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rondón Madrigal]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bello Rivero]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoma basocelular tratado con HeberFERON, seguimiento clínico, histológico y ecográfico. Reporte de caso]]></article-title>
<source><![CDATA[Gac. Méd. Espirit]]></source>
<year>2020</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>119-28</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez Castillo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Alfaro]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Salas Boza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisión sistemática del carcinoma basocelular]]></article-title>
<source><![CDATA[Rev.méd.sinerg]]></source>
<year>2020</year>
<volume>5</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez Salafranca]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zaballos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dermatoscopia del carcinoma basocelular: revisión actualizada]]></article-title>
<source><![CDATA[Actas Dermosifiliogr]]></source>
<year>2021</year>
<volume>112</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>330-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ariza]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Naranjo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nonsurgical Therapies for Basal Cell Carcinoma: A Review]]></article-title>
<source><![CDATA[Actas Dermosifiliogr]]></source>
<year>2017</year>
<volume>108</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>809-17</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bello Rivero]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia Vega]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Duncan Roberts]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Vazquez Blomquistc]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment]]></article-title>
<source><![CDATA[Semin Oncol]]></source>
<year>2018</year>
<volume>45</volume>
<numero>1-2</numero>
<issue>1-2</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santiesteban Aguilar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rosabal Fernández]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer Rosabal]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización clínica e histopatológica del carcinoma basocelular]]></article-title>
<source><![CDATA[Revdosdic]]></source>
<year>2018</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>37-47</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uribe]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Anaya]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Céspedes]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Prada]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Rueda]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoma basocelular de piel en el área metropolitana de Bucaramanga, Colombia: una mirada epidemiológica]]></article-title>
<source><![CDATA[Rev Asoc Colomb Dermatol]]></source>
<year>2018</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>18-23</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kwasniak]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia Zuazaga]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Basal cell carcinoma: evidence-based medicine and review of treatment modalities]]></article-title>
<source><![CDATA[Int J Dermatol]]></source>
<year>2011</year>
<volume>50</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>645-58</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Martínez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Millares López]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Asociación de radiación ultravioleta, fototipo de piel e histopatología del cáncer no melanoma. 7mo Congreso Virtual Hispanoamericano de Anatomía Patológica]]></source>
<year>2005</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carucci]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Leffell]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pettersen]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoma Basocelular]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Lowell]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Goldsmith]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Katz]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Gilchrest]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Paller]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Leffell]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
</person-group>
<source><![CDATA[Fitzpatrick. Dermatología en Medicina General]]></source>
<year>2014</year>
<edition>8</edition>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Médica Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez Linares]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Cifuentes Suarez]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Cuervo]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Román Simón]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez García]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bello Rivero]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoma basocelular del rostro tratado con HeberFERON]]></article-title>
<source><![CDATA[Gac. Méd. Espirit]]></source>
<year>2019</year>
<volume>21</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>87-97</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Negrín Caceres]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera Romero]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Cárdenas Monzón]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer Pérez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Batista Hernández]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento del carcinoma basocelular periocular con una combinación sinérgica de interferones alpha2b y gamma]]></article-title>
<source><![CDATA[Rev. Mex. Oftalmol]]></source>
<year>2018</year>
<volume>92</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>136-43</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kafle]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Hamal]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sahu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Poudyal]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sahu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinico-pathological Analysis of Malignant Eyelid and Adnexal Tumors Presenting to a Tertiary Eye Hospital of Eastern Nepal]]></article-title>
<source><![CDATA[BJHS]]></source>
<year>2020</year>
<volume>4</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>840-4</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrá Torres]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Rodríguez]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Ballester Caballero]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sallary Gutiérrez]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización de pacientes con carcinoma basocelular tratados con HeberFERON]]></article-title>
<source><![CDATA[Arch. méd. Camagüey]]></source>
<year>2020</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Armas Morell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sotolongo Díaz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Efectividad del HeberFERON en el tratamiento del carcinoma basocelular]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Ciego de Ávila ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anasagasti Angulo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Collazo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jimenez Barban]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tijerino Arrieta]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ballester Caballero]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HeberFERON, formulation based on IFNs alpha2b and gamma for the treatment of non-melanoma skin cancer]]></article-title>
<source><![CDATA[AMJ]]></source>
<year>2017</year>
<volume>10</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>509-15</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
